Logo
14.08.2018

Article

Dr. Klaus Moosmayer Selected as Novartis’ Chief Ethics Risk and Compliance Officer

With this appointment, Dr. Moosmayer will replace Shannon Thyme Klinger who was recently appointed Group General Counsel of the company. He is expected to commence operations from December 1, 2018.

read...
Logo
16.05.2018

Article

Novartis Makes Changes to the Executive Committee

The Group General Counsel of the firm, Felix R. Ehrat is expected to retire on June 1, 2018 following which Shannon Thyme Klinger will lead the team. Robert Weltevreden has also been appointed as Head of Novartis Business Services.

read...
Logo
12.03.2018

Article

Novartis Appoints New Members to its Executive Committee

Bertrand Bodson, Steffen Lang and Shannon Klinger have been appointed to the Executive Committee of Novartis (ECN).

read...
Logo
05.09.2017

Article

Unexpected Change in Novartis Management

Novartis announced a change in their management team: Vasant (Vas) Narasimhan will replace Joseph Jimenez as Chief Executive Officer.

read...
Logo
05.09.2017

Article

Unexpected Change in Novartis Management

Novartis announced a change in their management team: Vasant (Vas) Narasimhan will replace Joseph Jimenez as Chief Executive Officer.

read...
Logo
05.09.2013

Article

Tomorrow's Drug Manufacturing: How the Pharmaceutical Industry Fights Cost Pressures

What formula is the pharmaceutical industry developing in the face of constantly increasing costs? How are companies coping with the growing regulatory pressure? What will production be like in tomorrow's world? There were serious topics on the agenda at the 20th anniversary of I...

read...